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Abstract
Background: The aim of this study was to assess the burden of respiratory disease, considering the influenza
A pandemic season (H1N1pdm09), within the Brazilian Network for Surveillance of Severe Maternal Morbidity,
and factors associated with worse maternal outcome.
Methods: A multicenter cross-sectional study, involving 27 referral maternity hospitals in five Brazilian regions. Cases
were identified in a prospective surveillance by using the WHO standardized criteria for potentially life-threatening
conditions (PLTC) and maternal near miss (MNM). Women with severe complications from respiratory disease identified
as suspected or confirmed cases of H1N1 influenza or respiratory failure were compared to those with other causes of
severe morbidity. A review of suspected H1N1 influenza cases classified women as non-tested, tested positive and tested
negative, comparing their outcomes. Factors associated with severe maternal outcome (SMO =MNM+MD) were
assessed in both groups, in comparison to PLTC, using PR and 95 % CI adjusted for design effect of cluster sampling.
Results: Among 9555 cases of severe maternal morbidity, 485 (5 %) had respiratory disease. Respiratory disease occurred
in one-quarter of MNM cases and two-thirds of MD. H1N1 virus was suspected in 206 cases with respiratory illness.
Around 60 % of these women were tested, yielding 49 confirmed cases. Confirmed H1N1 influenza cases had worse
adverse outcomes (MNM:MD ratio < 1 (0.9:1), compared to 12:1 in cases due to other causes), and a mortality index >
50 %, in comparison to 7.4 % in other causes of severe maternal morbidity. Delay in medical care was associated with
SMO in all cases considered, with a two-fold increased risk among respiratory disease patients. Perinatal outcome was
worse in cases complicated by respiratory disease, with increased prematurity, stillbirth, low birth weight and Apgar
score < 7.
Conclusions: Respiratory disease, especially considering the influenza season, is a very severe cause of maternal near
miss and death. Increased awareness about this condition, preventive vaccination during pregnancy, early diagnosis and
treatment are required to improve maternal health.
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Background
Improvement in maternal health aiming a reduction in
maternal mortality is a priority worldwide, in an attempt
to accomplish the established millennium development
goals set for 2015 [1–3]. However, the expected reduc-
tion in maternal mortality is still far from ideal and var-
ies widely across regions [4, 5]. Most recently, to better
comprehend the burden of disease on female health and
complement mortality inquiries, an alternative approach
has been to study maternal morbidity. Maternal morbid-
ity can have an impact on both low-income and high-
income settings.
In 2009, the World Health Organization (WHO) stan-
dardized the definitions of potentially life-threatening
conditions (PLTC) and maternal near miss (MNM) [6].
PLTC is defined by the number of maternal complica-
tions, including hemorrhagic (e.g., abruption placenta,
ruptured uterus, atony and others), hypertensive disor-
ders (e.g., severe preeclampsia, eclampsia, HELLP syn-
drome), management indicators of severity (e.g., blood
transfusion, intubation, intensive care unit admission)
and other complications (e.g., pulmonary edema, cardiac
disease and sepsis). Maternal near miss (MNM) is any
situation in which a woman survives a very severe com-
plication with proven organ dysfunction, during preg-
nancy or puerperium (42 days after childbirth), with at
least one of the following criteria: clinical (e.g., shock or
clotting disorder), laboratory (lactate > 5, PaO2/FiO2 <
200 mmHg) or management (hysterectomy due to infection
or hemorrhage and blood transfusion ≥ 5 units of packed
red blood cells). Severe Maternal Outcome (SMO) ac-
counts for cases of MNM plus Maternal Deaths (MD) [6].
Recently, the concept of “obstetric transition” was in-
corporated into the study of maternal morbidity and
mortality. The concept illustrates a global trend in which
a pattern of high maternal mortality rates with predom-
inantly direct obstetric causes (e.g., hemorrhage, pre-
eclampsia or uterine infection) has been replaced by
lower maternal mortality rates with an increasing pro-
portion of indirect causes (preexisting disorders or those
aggravated by pregnancy, such as cardiac disease, kidney
disease or infection due to urinary or pulmonary foci),
institutionalization and medicalization of childbirth and
increased rate of obstetric interventions [7]. Obstetric
transition is important to help understand the occur-
rence of severe maternal morbidity and provide patients
with the appropriate treatment in different settings.
Among the indirect causes of maternal morbidity and
mortality, respiratory disease plays a significant role, either
due to the presence of severe infection or complications
of the underlying conditions, such as asthma and heart
disease. Physiological and anatomical changes that occur
during pregnancy to provide accommodation for the
growing uterus, can affect the known clinical presentation
of respiratory signs and symptoms. Adequate diagnosis
and treatment of respiratory disease may be delayed [8, 9].
In addition, it is recognized that pregnancy may in-
crease the risk of severe influenza-associated compli-
cations [10, 11].
It became clear throughout the 2009 H1N1 influenza
pandemic [termed A(H1N1)pdm09] worldwide [12–17]
that pregnant women were a highly vulnerable group.
From July 2009 to January 2, 2010, 44,544 cases of the
disease and 2051 deaths were reported in Brazil, [18].
However, the total number of cases and deaths were
likely much higher than the notified number.
We proposed a novel approach to analyzing the bur-
den of 2009 H1N1 influenza virus infection and other
respiratory disease among patients with severe maternal
morbidity. Cases complicated by severe respiratory dis-
ease were compared to cases with morbid conditions
due to other causes (such as hemorrhage and hyperten-
sion). In addition, factors possibly associated with a
higher risk of SMO were evaluated by using the WHO
standardized definitions of morbidity in 27 referral ma-
ternity hospitals.
Methods
This study is a secondary analysis of the Brazilian Net-
work for Surveillance of Severe Maternal Morbidity in-
cluding 27 referral maternity hospitals in Brazil. The
study evaluated severe maternal morbidity cases, from a
prospective surveillance, according to the 2009 WHO
newly publicized criteria for these conditions [6].
The methodological details of the original study have
already been published elsewhere [19, 20]. Briefly, this
multicenter study included 27 referral maternity hospi-
tals distributed among the five Brazilian geographical re-
gions. From July 2009 to June 2010, all women admitted
to participating centers, who were identified as having
any life-threatening condition, near miss or maternal
death, according to the WHO definition, were included
in the study. Data collection, by the study team, was ac-
quired through medical chart review after hospital dis-
charge or death of the patient. If any doubt on diagnosis
considered, the treating doctors were further contacted
for clarifications. Information was entered into the
OpenClinica® electronic platform (version 2.5.5 -
Waltham, MA, USA) through a structured form completed
by the local coordinator from each participating center.
This was not a population based study, however, there
was a concern to reduce the impact of nonrandom sam-
pling and an effort to consider representativeness of the
national territory (with health facilities from all five
macro-regions of the country) and of facilities from
public and private sectors, university and non-university
hospitals. All selected hospitals had to provide informa-
tion concerning their characteristics, including location,
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complexity of level of care, population covered, number of
maternity beds and availability of resources for severe cases.
Quality control was carried out during various phases of
the study. Initially, training was provided to the entire
team participating in the study, using a detailed operations
manual, with the definition of each variable. Meetings
were held between the local research team and the coord-
inating team of the study to standardize data. Case review
was conducted by the local investigator. Subsequently, the
coordinating team of the study performed random reviews
of manual and electronic forms for data consistency in
visits to monitor the centers’ performance. Periodically,
review of the electronic system was carried out to check
for data inconsistency, along with systematic case review.
Some reported conditions were delay or substandard care,
which had been previously reported [21]. Reasons for the
delay in treatment were the woman or family member
(including delay in identifying the condition, seeking care
and refusing to accept treatment), health service (difficul-
ties in obtaining equipment or medical supplies) or health
professional (delays in identifying the correct diagnosis
and providing appropriate patient treatment). Sample size
was determined by the prevalence of about 8 maternal
near miss cases per 1000 births and a maternal mortality
ratio of 140/100,000 live-born infants (95 % confidence
interval). It was predicted that 75,000 births [19] needed
to be monitored.
For the present analysis, we considered severe respira-
tory disease as a suspected or confirmed case of influ-
enza or acute respiratory failure, defined as incapacity of
the respiratory system to promote adequate gas ex-
change, with arterial blood gas parameters: PaO2 <
60 mmHg or peripheral saturation < 90 %, associated or
not with PaCO2 > 50 mmHg. Clinical parameters such
as tachypnea (respiratory rate-RR > 20) or bradypnea
(RR <6), use of accessory respiratory muscles, nasal
flaring, associated with torpor or agitation were also
considered. For suspected or confirmed cases of
A(H1N1)pdm09, the definition of cases considered only
those with severe morbidity, including acute respiratory
insufficiency, sepsis, intensive care admission, intubation
and others. Cases of H1N1 without severe complications
were not included. A review of all H1N1 Influenza cases
was necessary to confirm whether laboratory tests had been
performed and to obtain the results of these tests, since
data in the original study had not been collected in detail.
Case review was requested from each local center and new
data were distributed into three groups: non-tested, positive
and negative cases for H1N1 influenza virus.
Initially, the prevalence of PLTC, MNM and MD was
calculated per group, as well as the respective health in-
dicators related to maternal morbidity and mortality:
maternal near miss ratio, severe maternal outcome ratio,
mortality index and maternal mortality ratio, according
to the WHO definition [6]. To evaluate the progression
of severe maternal morbidity in cases complicated by re-
spiratory disease throughout the study, maternal out-
comes (PLTC, MNM and MD) were measured for each
month studied. The risk of SMO associated with proce-
dures used to manage the severity of conditions was esti-
mated for the group with severe respiratory disease and
other causes of severe maternal morbidity, using Preva-
lence Ratios plus their respective 95 % CI adjusted for
the design effect of cluster sampling.
Subsequently, we performed an analysis considering
the total number of cases with severe respiratory disease
versus cases with other causes of severe maternal mor-
bidity. In each group, PLTC (less severe cases) and Se-
vere Maternal Outcome (SMO: MNM+MD) cases were
compared to evaluate the factors potentially associated
with more severe disease, including delay in obstetric
care, also using the Prevalence Ratios plus their respect-
ive 95 % CI adjusted for the design effect of cluster sam-
pling. The prevalence of sociodemographic, obstetric
and perinatal factors were evaluated between the two
groups using Chi-square tests. Values statistically signifi-
cant were considered those with a p-value under 0.05.
The statistical procedures for analysis were performed
with SPSS and Stata.
Results
During the 12-month study period, 82,388 women were
screened. Of these, 9555 had criteria for severe maternal
morbidity. Among these 9555 women, only 485 (5 %)
had severe respiratory disease. However, in this group
with respiratory illness, symptom severity progressed
more rapidly, if compared to other causes of severe mor-
bidity (Fig. 1), such as bleeding or hypertensive disor-
ders, and may be 40 times more lethal.
Among the total number of women with respiratory
disease, patients with suspected H1N1 influenza A virus
infection had more severe disease (55.2 % MNM and
23.3 % MD) than those without suspected H1N1 influ-
enza A virus (prevalence of MNM: 21.3 %, MD: 14.1 %)
(Fig. 1). About 60 % of cases of suspected H1N1in-
fluenza A were tested. Women who tested positive (49
cases) for H1N1 had more severe disease, with a higher
prevalence of SMO.
Figure 2 shows the distribution of cases with severe re-
spiratory disease, according to progression of severity
during the study period, based on date of admission in
participating centers. There was a higher incidence of
cases in the first months considered, especially July, Au-
gust and September 2009. National guidelines and avail-
ability of vaccination during pregnancy were instituted
in March/2010.
Considering health indicators, disease was more severe
among cases tested and positive for H1N1 (Table 1).
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Mortality rate was higher than 50 % among positive
cases for A(H1N1)pdm09. The death rate was about
36 % in cases testing negative for H1N1 and 27.5 % in
non-tested cases. In contrast, the mortality rate was only
7.4 % in morbid disorders due to other causes. The ma-
ternal near miss to mortality ratio was 0.93:1, 1.80:1 and
2.39:1, among positive, negative and non-tested groups
for A(H1N1)pdm09, respectively, compared to a value of
12.43:1 for other causes of severe maternal morbidity.
More than 55 % of patients with severe respiratory dis-
ease had three diagnostic criteria for near miss: laboratory,
clinical and management, while for the remaining causes
of severe maternal morbidity, around 24 % of patients only
had criteria for laboratory or management diagnosis
(Table 2). All procedures for management of severity were
associated with a worse outcome in both groups, women
with severe respiratory disease and those with severe ma-
ternal morbidity due to other causes (Table 3).
Analysis of sociodemographic and obstetric character-
istics (Table 4) compared cases of PLTC and SMO for
both groups: with severe respiratory disease and other
causes of morbidity. For the respiratory complications,
Overall Screened women = 82388
SMM = 9555 (11.6%)
PLTC = 8645 (90.5%)
MNM = 770 (8.0%)
MD = 140 (1,5%)
With Respiratory disease = 485
PLTC = 193 (39.8%)
MNM = 198 (40.8%)
MD = 94 (19.4%)
Whitout suspected A(H1N1)pdm09 = 279
PLTC = 60 (21,5%)
MNM = 154 (55,2%)
MD = 65 (23,3%)
Non tested for A(H1N1)pdm09= 74
PLTC = 56 (75.7%)
MNM = 13 (17.6%)
MD = 5 (6.7%)
Positive for A(H1N1)pdm09 = 49 
PLTC = 22 (44.9%)
MNM = 13 (26.5%)
MD = 14 (28.6%)
Negative for A(H1N1)pdm09 = 83 
PLTC = 55 (66.3%)
MNM = 18 (21.7%)
MD = 10 (12.0%)
With suspected A(H1N1)pdm09 = 206
PLTC = 133 (64.6%)
MNM = 44 (21.3%)
MD = 29 (14.1%)
With other causes SMM = 9070 
PLTC = 8452 (93.2%)
MNM = 572 (6.3%)
MD = 46 (0.5%)
Fig. 1 Flow chart of women with severe maternal morbidity (SMM = PLTC +MNM+MD) due to severe respiratory disease or other causes of
morbidity and suspected influenza A(H1N1)pdm09 as positive, negative or not tested, considering the final maternal outcome in potentially
life-threatening condition (PLTC), maternal near miss (MNM), or maternal death (MD)
0
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Fig. 2 Distribution of cases with severe respiratory disease, according to progression of severity during the study period
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there was an association to SMO and non-white color,
history of diabetes, low weight and substance abuse (use
of psychoactive substances, including alcohol and illicit
drugs), in addition to delay in care. In contrast, the
group of cases due to other causes of morbidity, low ma-
ternal age, first pregnancy, history of maternal obesity
and lack of a partner were identified as having lower asso-
ciation to SMO, while hospitalization in a non-public in-
stitution, parity, history of caesarian section, drug abuse,
complication occurrence at an earlier gestational age and
mainly in the postpartum period, in addition to any type
of delay in obstetric care, were associated with SMO.
Concerning characteristics of pregnancy and perinatal
results (Table 5), the group with severe respiratory dis-
ease had a higher rate of early preterm births, between
22 and 33 weeks of gestation, low birthweight (<2500 g),
Apgar < 7 at five minutes of life, stillborn and the need
for hospital admission/transference of the newborn in-
fant, compared to the group with severe maternal mor-
bidity due to other causes. Neonatal death increased
threefold in women with severe respiratory disease. A
statistically significant difference was observed in the
groups compared, when the mode of delivery and onset
of labor were taken into consideration (p < 0.001). The
number of women who did not undergo pregnancy reso-
lution and remained pregnant during the severe morbid
event was much higher in the respiratory disease group.
Around 35 % were “still pregnant” compared to 5 % in the
group with severe maternal morbidity due to other causes.
Discussion
Our study presents the burden of severe respiratory dis-
eases among cases of severe maternal morbidity and re-
sults of the 2009 H1N1 influenza pandemic, considering
27 referral maternity hospitals in Brazil. Overall, the
prevalence of respiratory disease was rare (5 %). Never-
theless, respiratory disease accounted for one-quarter of
MNM cases and two-thirds of MD. Worse adverse out-
comes occurred among cases of confirmed
A(H1N1)pdm09, with an impressive MNM:MD ratio
below one, meaning that there were more deaths than
near miss cases in this group.
The mortality index (MI) was over 50 % in the H1N1
group, compared to 7.4 % for other causes of severe ma-
ternal morbidity. The MI is known to correlate to qual-
ity of care and when the index is above 20 %, it
represents substandard care [22]. Numbers of MI over
50 % most likely reflect that poor outcomes were not
only due to the severity of disease, but also to substand-
ard care, including delays in diagnosis and management
of the considered cases. Our data further confirmed that
the increased risk of SMO was linked to delays in health
care (delays due to women/family members, health ser-
vices or health professionals).
Considering the impact of the A(H1N1)pdm09 on ma-
ternal health [10], a great effort towards prevention oc-
curred worldwide, with strong recommendations for
vaccination during pregnancy and empirical antiviral
Table 1 Women with severe respiratory disease: cases non-tested for influenza A(H1N1)pdm09, influenza A(H1N1)pdm09 positive,
influenza A(H1N1)pdm09 negative and other causes of morbidity according to severity of outcome (PLTC, MNM, MD) and their
correspondent health indicators
Conditions PLTC MNM MD Total Health indicators
MNMR/ 1000LB SMOR/ 1000LB MNM:MD ratio Mortality index % MMR/ 100000LB
Influenza A(H1N1)pdm09
positive
22 13 14 49 0.16 0.33 0.93:1 51.8 17.0
Influenza A(H1N1)pdm09
negative
55 18 10 83 0.22 0.34 1.80:1 35.7 12.2
Non-tested for influenza
A(H1N1)pdm09
116 167 70 353a 2.03 2.89 2.39:1 29.5 85.2
Total Respiratory disease 193 198 94 485 2.41 3.55 2.11:1 32.2 114.4
Other causes 8452 572 46 9070 6.96 7.52 12.43:1 7.4 56.0
LB: 82.144
LB: live births; PLTC: potentially life-threatening condition; MNM: maternal near miss; MD: maternal death; MNMR: maternal near miss ratio; SMOR: severe maternal
outcome ratio = (MNM +MD)/LB X 1000; MNM:MD ratio = MNM:1MD; Mortality index = MD/(MNM +MD); MMR: maternal mortality ratio = MD/LB X100.000
aNon-tested for influenza A(H1N1)pdm09 = includes suspected Influenza (74) + without suspected Influenza (279)
Table 2 Prevalence of maternal near miss criteria in women
with severe respiratory disease or other causes of severe
maternal morbidity
Maternal Near Miss criteria Respiratory Other causes p*
n % N %
<0.001
Clinical only 20 6.8 93 15.0
Laboratory only 21 7.2 151 24.4
Management only 22 7.5 153 24.8
Clinical + Laboratory 15 5.1 23 3.7
Clinical + Management 41 14.0 82 13.3
Laboratory + Management 12 4.1 30 4.9
Clinical + Laboratory + Management 161 55.1 86 13.9
*Adjusted for design effect of cluster sampling
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therapy, as soon as possible in case of suspected disease
[10]. Brazil followed these recommendations and
launched a national vaccination campaign before the
winter of 2010, targeted at high-risk groups, including
pregnancy. The vaccine was available in all public health
facilities, at no cost for the patient and reached very high
coverage (around 80 %), most likely due to the long term
experience in the National Immunization Program for
Children and due to the awareness about the severity of
the disease, among health professionals and among the
society [23]. We cannot evaluate the impact of those
preventive measures in our study, since we lack informa-
tion on the total number of cases and specific data on
individual history of vaccination or treatment, however,
from our Fig. 2, we can see on the linear traces that
there is a trend towards decrease in numbers of severe
cases, through time, especially after vaccination.
Clinical evaluation should determine treatment, in
order to ensure timely and effective interventions. In our
study, around 60 % of suspected cases of H1N1 influ-
enza A virus were tested. In accordance with previous
reports, symptoms were more severe in positive cases
[24]. The majority of cases in Brazil occurred during
cold weather (July, August and September), period of in-
creased infections by respiratory viruses and influenza
outbreak in the country (Brazil declared a pandemic in
mid-July 2009).
Over half of the reported cases of severe respiratory
disease were not due to suspected influenza infection.
Acute respiratory failure was the cause, including a
broad number of conditions, as follows: pulmonary
edema, cardiac disease community-acquired pneumo-
nia, aspiration, pulmonary embolism, asthma exacer-
bation or venous embolism. Unfortunately we do not
have detailed information on each of the mentioned
causes.
Nevertheless, these complications include mostly in-
direct causes of maternal morbidity and mortality, which
represent novel or preexisting health problems unrelated
to pregnancy, such as cardiac disease and asthma.
Asthma is the most common medical condition that
may worsen during pregnancy and it is often underdiag-
nosed and under-treated [9]. Direct causes of maternal
morbidity and mortality can also lead to respiratory fail-
ure, such as systemic consequences of sepsis due to uter-
ine infection and severe preeclampsia and eclampsia,
complicated by pulmonary edema [25, 26].
It is very important to understand all differential
diagnosis, since timely and adequate interventions can
potentially improve maternal outcome. Future studies
focusing on the specific differences in diagnosis and
management of causes of acute respiratory failure
should consider the main aspects on diagnosis and
management of these conditions. Pneumonia in preg-
nancy and postpartum, for example, is the leading
cause of fatal none obstetric infection and can be caused
by bacteria, virus (at risk of secondary bacterial infection),
fungus and mycobacteria and the clinical features include
fever, cough, dyspnea and hypoxia [9].
Another important cause of severe complications is pul-
monary edema, which can be consequence of left ven-
tricular systolic or diastolic dysfunction, or due to the use
of tocolytic agent, fluid overload, severe hypertension or
severe renal disease. The clinical presentation of pulmon-
ary edema is normally dyspnea, tachypnea, tachycardia,
chest pain and diffuse crackles. There can be evidence of
cardiac dysfunction, specific alterations in the electrocar-
diogram and radiographic abnormalities [27].
Table 3 Estimated risk of severe maternal outcome (SMO) among women with severe respiratory disease or other causes of severe
maternal morbidity according to management procedures used for severity
Procedures associated with severity Respiratory PR 95 % CI* Other causes PR 95 % CI*
SMO PLTC SMO PLTC
Blood transfusion 146 13 2.05 1.38–3.05 397 1010 9.78 7.26–13.18
Central venous access 190 11 2.63 1.71–4.06 125 37 13.94 10.30–18.88
ICU admission 262 75 3.84 1.94–7.59 364 1414 5.88 3.44–10.05
Hospital stay >7 days 211 65 1.97 1.32–2.95 322 2270 2.72 1.84–4.03
Invasive mechanical ventilation 204 1 3.17 2.08–4.81 86 5 15.95 11.85–21.48
Use of vasoactive drug 148 0 2.34 1.60–3.43 96 0 17.19 12.90–22.90
Transfusion of ≥5U packed red blood cells 60 0 1.83 1.37–2.45 189 0 20.70 16.15–26.53
Intubation and ventilation ≥60 min not related with anesthesia 210 0 3.35 2.23–5.05 85 0 16.86 12.70–22.37
Dialysis for acute renal insufficiency 34 0 1.75 1.35–2.26 29 0 15.35 11.52–20.46
CPR 84 0 1.93 1.46–2.55 36 0 15.52 11.66–20.67
Values in bold mean they are statistically significant (p < 0.05)
SMO severe maternal outcome (maternal near miss plus maternal death); PLTC potentially life-threatening condition; PR prevalence ratio adjusted for cluster design
effect; CI confidence interval; ICU intensive care unit; CPR cardiopulmonary resuscitation
*Adjusted for design effect of cluster sampling
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Table 4 Estimated risk of severe maternal outcome (SMO) among women with severe respiratory disease or other causes of severe
maternal morbidity according to sociodemographic and obstetric characteristics, medical history and delay in care
Variables Respiratory PR 95 % CI* Other causes PR 95 % CI*
SMO PLTC SMO PLTC
Age (years)
≤ 19 59 33 1.11 0.90–1.38 80 1541 0.73 0.59–0.89
20–34 176 130 1.00 401 5513 1.00
≥ 35 57 30 1.14 0.97–1.34 137 1398 1.32 1.05–1.64
Marital statusa
With partner 152 100 1.00 317 3704 1.00
Without partner 84 57 0.99 0.76–1.28 159 3466 0.56 0.40–0.78
Educationb
Elementary 91 62 1.00 192 2871 1.00
> Elementary 89 62 0.99 0.77–1.28 188 3368 0.84 0.66–1.08
Skin Colorc
White 133 112 1.00 247 2539 1.00
Non white 115 62 1.20 1.01–1.41 229 3702 0.66 0.43–1.01
Number of pregnanciesd
1 117 65 1.12 0.92–1.38 194 3599 0.65 0.56–0.75
2 or more 170 127 1.00 411 4810 1.00
Number of childbirthsd
0 132 74 1.00 210 4160 1.00
1 or more 155 118 0.89 0.73–1.08 395 4249 1.77 1.55–2.02
Previous C-sectionse
0 217 129 1.00 402 6363 1.00
1 or more 61 63 0.78 0.59–1.04 184 1940 1.46 1.22–1.74
Medical historyf
Chronic hypertension 30 17 1.11 0.88–1.41 84 1325 0.90 0.66–1.23
Diabetes 12 3 1.39 1.04–1.86 21 173 1.69 0.94–3.07
Smoking 21 23 0.80 0.58–1.12 32 390 1.18 0.68–2.04
Obesity 39 36 0.88 0.68–1.12 66 1848 0.46 0.30–0.70
Low weight 5 0 1.73 1.33–2.27 1 21 0.70 0.09–5.30
Respiratory disease 26 31 0.76 0.48–1.20 11 166 0.96 0.62–1.46
HIV/AIDS 9 9 0.85 0.51–1.44 6 67 1.27 0.56–2.88
Substance abuse 14 4 1.36 1.06–1.74 11 71 2.09 1.20–3.63
Prenatal coverageg
Public 206 134 1.00 430 5890 1.00
Other 34 15 1.15 0.85–1.54 69 746 1.24 0.82–1.88
Prenatal adequacyh
No 56 36 1.00 0.81–1.22 109 1925 0.75 0.60–0.94
Yes 212 135 1.00 476 6197 1.00
Hospitalization coveragei
Public 285 187 1.00 602 8366 1.00
Other 6 6 0.83 0.44–1.54 16 78 2.54 1.43–4.50
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During labor or immediate postpartum, a rare and
feared complication is the aspiration of gastric contents,
if needed intubation for general anesthesia, due to in-
creased intraabdominal pressure and predisposing
physiological changes of pregnancy such as relaxation of
the lower esophageal sphincter and delayed gastric
emptying. However, in the last decades, the incidence of
aspiration significantly declined, even with food intake
during labor [28].
The definitions of severe respiratory complications
that are usually reported can be rather confusing and
sometimes difficult to incorporate [29]. Recent onset
of fever and respiratory symptoms, including cough is
the clinical definition of Severe Acute Respiratory
Syndrome. In the setting of an epidemic, this defin-
ition is very useful to raise awareness and ensure
prompt treatment, as soon as a suspected case is
identified [30]. ARDS is another acronym for Acute
Respiratory Distress Syndrome, a different condition
that represents hypoxemic respiratory failure and bi-
lateral radiographic opacities, without congestive heart
failure. This diagnosis depends on oxygenation deficit
measurements and chest imaging [31, 32].
In the current study, we couldn’t accurately establish
any of the above conditions, since we did not collect
data on clinical symptoms (fever, cough) neither ob-
tained the results of those specific laboratory findings or
imaging. The diagnosis of H1N1 influenza was also not
standardized through all hospitals included. We under-
stand that timing of sample collection, quality of sample
and laboratory procedures are key for the accurate diag-
nosis and unfortunately we do not have data on details
regarding these procedures.
Another limitation was the lack of data on the use of
antiviral therapy or vaccination. For cases of SMO,
complicated by documented organ dysfunction, ARDS
would probably be the diagnosis of respiratory disease.
Nevertheless, confirmation was lacking for all cases. In
addition, we do not have a control group, with no
underlying complication, what would be key to access
risk factors. We only have data on severe maternal mor-
bidity cases, comparing less severe (PLTC) to more se-
vere cases (SMO).
Factors associated with SMO, included non-white color,
history of diabetes, low weight and substance abuse, along
with delay in care, were reported for the majority of condi-
tions under study. Substance abuse associated with in-
creased risk of severity in cases of respiratory disease, is in
agreement with previous reports [33, 34]. Drug-related se-
vere respiratory complications can occur, resulting from
parenchymal (infectious and non-infectious pneumonitis,
aspiration-related events, hemorrhage, pulmonary edema
and pneumothorax), pulmonary vascular insults (endovas-
cular infection, hemorrhage, and vasoconstriction) or air-
way (bronchospasm and hemorrhage) abnormalities.
Diabetes was also associated with an increased risk of
SMO among cases complicated by severe respiratory dis-
ease. Previous studies had demonstrated this fact, even in
the Brazilian population. Diabetes is one of the main risk
factors for death from H1N1 influenza A [35] virus infec-
tion. Medical history, including known factors related to
worse outcomes should be highlighted and the awareness
among patients and health professionals towards targeted
cases could impact in the final outcome.
Pregnancy characteristics and perinatal outcomes ac-
cording to the main cause of severe morbidity showed
that pregnancies complicated by respiratory disease
present an increased rate of preterm delivery and worse
perinatal outcomes. This finding had already been dem-
onstrated [10, 36]. Studies have shown that vaccination
Table 4 Estimated risk of severe maternal outcome (SMO) among women with severe respiratory disease or other causes of severe
maternal morbidity according to sociodemographic and obstetric characteristics, medical history and delay in care (Continued)
Gestational age at hospital admissionj
< 22 36 42 0.72 0.50–1.02 47 406 3.36 1.77–6.37
22–36 161 117 0.90 0.69–1.17 297 3604 2.47 1.70–3.58
≥ 37 38 21 1.00 125 3926 1.00
Postpartum 51 12 1.26 0.97–1.63 124 290 9.71 6.20–15.20
Delays
Women/family membersk 124 53 1.42 1.11–1.82 218 2902 1.14 0.89–1.44
Health servicel 109 12 1.85 1.36–2.51 166 1089 2.35 1.66–3.33
Health professionalm 112 9 1.93 1.47–2.55 167 1260 2.07 1.41–3.04
Any delaysn 213 63 2.39 1.60–3.56 367 4044 1.74 1.36–2.24
SMO severe maternal outcome (maternal near miss plus maternal death); PLTC potentially life-threatening condition; PR prevalence ratio adjusted for cluster design
effect; CI confidence interval; ICU intensive care unit
Values in bold mean that they are statistically significant (p < 0.05)
Missing information for: a 92 and 1424 (respiratory and other causes); b 181 and 2451; c 63 and 2353; d 6 and 56; e 15 and 181; f 43 and 1271; g 96 and 1935; h 46
and 363; i 1 and 8; j 7 and 251; k 71 and 1104; l 15 and 692; m 17 and 607; n 39 and 800 cases
*Adjusted for design effect of cluster sampling
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during the first trimester of pregnancy can improve
those outcomes and decrease stillbirth rates without in-
creasing the risk of malformations, which is a common
concern among health practitioners and pregnant
women [37].
Conclusion
Severe respiratory disease, especially considering the in-
fluenza season, is one of the most serious causes of ma-
ternal near miss and death. Increased awareness of this
condition, preventive vaccination during pregnancy,
early diagnosis and treatment are required to improve
maternal health.
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